header logo image


Page 689«..1020..688689690691..700710..»

Genetic engineering company says they have created a coronavirus vaccine – 9News.com KUSA

February 25th, 2020 5:43 pm

HOUSTON A Houston-based genetic engineering company said it has a vaccine aimed at the deadly coronavirus outbreak, according to a report by the Houston Business Journal.

The genetic engineering firm, Greffex Inc. has one of its laboratories based in Aurora, Colorado.

RELATED: Coronavirus death toll hits 2,100 in mainland China

RELATED: Colorado man living in China posts brutally honest Instagram videos of coronavirus self-quarantine

John Price, president and CEO of Greffex Inc., told KHOU, our sister station in Houston, that Greffex's scientists completed the coronavirus vaccine this week.

The trick in making a vaccine is can you scale the vaccine that youve made to be able to make a certain number of doses, can you test the vaccine quickly and efficiently and then can you get it into patients and thats where we have an edge as well on the other companies that are out there," said Price. "And that has to do with speed and essential uniformity of how we make vaccines, so that drops the cost down.

Price said the vaccine will now move into a testing phase with the Food and Drug Administration.

The Houston Business Journal reported, in September 2019 Greffex received an $18.9 million contract from the National Institute of Health's National Institute for Allergy and Infectious Diseases to develop new treatments for infectious threats.

If the vaccine gets government approval, Price said his company plans to give it away for free to nations hit hard by the coronavirus outbreak.

SUGGESTED VIDEOS | Local stories from 9NEWS

More here:
Genetic engineering company says they have created a coronavirus vaccine - 9News.com KUSA

Read More...

Global Gene Therapy Market Projected to Grow with a CAGR of 34.8% During the Forecast Period, 2019-2026 – ResearchAndMarkets.com – Yahoo Finance

February 25th, 2020 5:43 pm

The "Gene Therapy Market by Vector Type, Gene Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

The global gene therapy market was valued at $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026.

Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient's cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.

Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.

The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.

Key MARKET BENEFITS FOR STAKEHOLDERS

Key Findings of the Gene Therapy Market:

Key Topics Covered:

Chapter 1: Introduction

1.1. Report Description

1.2. Key Benefits

1.3. Key Market Segments

1.4. Research Methodology

Chapter 2: Executive Summary

2.1. CXO Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope

3.2. Key Findings

3.3. Top Player Positioning, 2018

3.4. Porter's Five Forces Analysis

3.5. Market Dynamics

Chapter 4: Gene Therapy Market, By Vector Type

4.1. Overview

4.2. Viral Vectors

4.3. Non-Viral Techniques

Chapter 5: Gene Therapy Market, By Gene Type

5.1. Overview

5.2. Antigen

5.3. Cytokine

5.4. Tumor Suppressor

5.5. Suicide Gene

5.6. Deficiency

5.7. Growth Factors

5.8. Receptors

5.9. Others

Chapter 6: Gene Therapy Market, By Application

6.1. Overview

6.2. Oncological Disorders

6.3. Rare Diseases

6.4. Cardiovascular Diseases

6.5. Neurological Disorders

6.6. Infectious Diseases

6.7. Other Diseases

Chapter 7: Gene Therapy Market, By Region

7.1. Overview

7.2. North America

7.3. Europe

7.4. Asia-Pacific

7.5. LAMEA

Chapter 8: Company Profile

8.1. Adaptimmune Therapeutics Plc.

8.2. Anchiano Therapeutics Ltd.

8.3. Achieve Life Sciences, Inc.

8.4. Adverum Biotechnologies, Inc.

8.5. Abeona Therapeutics Inc.

8.6. Applied Genetic Technologies Corporation

8.7. Arbutus Biopharma Corporation

8.8. Audentes Therapeutics Inc.

8.9. Avexis Inc.

8.10. Bluebird Bio, Inc.

8.11. Celgene Corporation

8.12. Crispr Therapeutics Ag

8.13. Editas Medicine, Inc.

8.14. Gilead Sciences, Inc.

8.15. Glaxosmithkline Plc

8.16. Intellia Therapeutics Inc.

8.17. Merck & Co., Inc.

8.18. Novartis Ag

8.19. Regenxbio, Inc.

8.20. Spark Therapeutics, Inc.

8.21. Sangamo Therapeutics, Inc.

8.22. Uniqure N. V.

8.23. Voyager Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/yt2y68

View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005742/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T. Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the original here:
Global Gene Therapy Market Projected to Grow with a CAGR of 34.8% During the Forecast Period, 2019-2026 - ResearchAndMarkets.com - Yahoo Finance

Read More...

Pet food makers look to tap the alternative meat market – Marketplace

February 25th, 2020 5:43 pm

New pet food companies are springing up to meet what they say is growing demand for plant-based, sustainable alternatives to Fancy Feast and Kibbles N Bits.

By making products from fermented fungus and experimenting with lab-grown food from animal cells and microbes, alternative pet food makers are hoping to carve out a share of the $30 billion U.S. pet food market.

And multibillion-dollar pet food companies, like Mars Petcare and Nestl-owned Purina, are starting to take notice.

Our mission is almost the exact same as Impossible Foods, which is [to] reduce or eliminate factory farming, which has this giant environmental footprint, said Josh Errett, CFO of Because Animals, one of the companies developing new pet foods. I mean, calling it a footprint is too nice, its an environmental disaster.

The other mission is to make a profit. These companies are catering to pet owners who value their ecological footprint and have the income to pay for an alternative product that tends to be more expensive than a can of Pedigree.

Pulling away from factory farming

A UCLA study from 2017 by Professor Gregory Okin estimated that dog and cat food accounts for the release of millions of tons of the greenhouse gases methane and CO2 and constitutes about 25%30% of the environmental impacts from animal production in terms of the use of land, water, fossil fuel, phosphate and biocides.

Like plant-based market leaders Impossible Foods and Beyond Meat, alternative pet food companies say their product will reduce the amount of land and energy used for conventional meat production.

Industrial animal farming, or concentrated animal feed operations, produce large amounts of byproducts and off-cuts like organs and bone meal which are not usually used in human food, but are re-purposed for pet food production.

The goal is to cut factory farming out of the supply chain completely without a market for the unused parts, the meat industry would collapse due to lost revenue, Errett said.

But many large pet food companies defend their use of animal byproducts.

One might argue that this is actually a super sustainable source, because were using materials that most of us wouldnt consume and would be wasted, said Richard Butterwick, global nutrition advisor at the Waltham Petcare Science Institute, a research center for Mars Petcare.

Because Animals along with another company, Wild Earth are using cellular technology to culture real meat from animal cells biopsied from living creatures. The cells are encouraged to proliferate and reproduce in a bioreactor, creating muscle protein without the need to slaughter animals. This process is also being used by more than 30 companies worldwide to develop clean or lab-grown meat for human consumption.

Next year, both Because Animals and Wild Earth hope to release their first cell-grown cat foods, made of cultured mouse meat.

Were getting back to what the cats system was built to digest, Errett said. You dont have to add taurine or anything back, you can make an ancestral diet.

A cat owner himself, Errett wanted to address the ultra-processed nature of a lot of the conventional cat food, or as he calls it biological waste. Cats are obligate carnivores, meaning they need to eat meat to get the 11 essential amino acids they require or they could have serious health problems like blindness or even death.

By culturing animal meat in a lab, these companies can genetically control what nutrients present in the food. They can also eliminate potentially dangerous substances that have made their way into some conventional pet foods. Some popular pet foods companies have had to recall their products in recent years due to toxic levels of Vitamin D and even the euthanasia drug sodium pentobarbital.

Will pet owners buy lab-grown mouse meat for their cats?

Beyond Meat increased its revenues by 250% between 2018 and 2019; consumers are taking an interest in the health and environmental benefits promoted by plant-based foods. Pet owners are showing that they will pay more for luxury and premium pet foods.

Wild Earth is making dog food from cultured fungi proteins and, according to CEO Ryan Bethencourt, revenue is growing steadily even though production is still relatively small.

This plant-based type of cultured pet food, already on the market, is much more expensive than the conventional options. A 18-pound bag of Wild Earth dog food sells for $49 on its website; whereas the website Chewy sells a 18.5-pound bag of Purina Dog Chow for $11.99.

Bethencourt said the potential for cultured protein could be 10% of the total pet food market within the next 10 years. He is using the success of plant-based proteins for humans as evidence for the market potential of alternative pet foods.

Research backs his point; according to one study from 2019, it is clear that an association exists between the diet a pet owner has chosen to follow and the diet they choose to feed their pet.

Culturing microbes into pet food

Another alternative pet food company, Bond Pet Foods, is taking a slightly different approach to cultured pet food. Bond is experimenting with genetically engineering microbes, like yeast.

Theres a lot more that isnt known about growing mice cells to create meat. Theres just a lot more technical challenges that they have to figure out how to ramp up and replicate that kind of meat production, said Rich Kelleman, CEO of Bond Pet Foods.

Bond is using the same approach to genetic engineering used to synthetically produce rennet for cheese production or insulin for diabetics.

What were doing is isolating a skeletal muscle protein so the building blocks of meat and inserting the DNA from that into a microbe, and then using the machinery of the microbe to produce identical animal proteins that you get on a farm and field, drying it down and then using that in a broader recipe to provide high quality nutrition, Kelleman said.

The major pet food companies are also looking for environmentally friendly, alternative proteins that could be inexpensive to scale up as a replacement for conventionally raised meat.

One area were currently exploring is looking at insects as a potential protein source, said Richard Butterwick at the Waltham Institute. They are potentially much more sustainable than traditional mammalian sources of protein and potentially very nutritious, as well.

Venture capital funds are eyeing the potential of cultured alternatives

Last year, Bond completed a $1.2 million seed round of funding and won a $10,000 innovation award from Purina.

Because Animals won this years innovation award and Wild Earth received a $200,000 investment from Mars Petcare during its 2018 investment round. So far, Wild Earth has raised over $16 million from various venture capital funds to pay for its continued growth.

These are relatively small amounts on the scale of the industry, but there is a sense of momentum.

All the big pet food manufacturers are looking at their supply chain and they see challenges with the growth of the pet food market and the population overall, more people means more pets, Kelleman said. Theyre looking for ways that they could mitigate the risk.

Richard Butterwick said that the main concern is that a pets nutritional needs are understood by their owners. He said consumer trends and the humanization of pets should not compromise pet needs, just because there is a trend towards more sustainable eating for humans.

A 2015 study in the Journal of Animal Science looked at the changing attitudes of pet owners choice in food for their companions. The study said it was paramount that sustainability be weighed against animals nutritional demands.

That means conscientious pet owners need to be wary of compromising a pets health just because eating kogi fungus, cricket treats, or lab-grown meats is trending for humans.

Related Stories

If youre a member of your local public radio station, we thank you because your support helps those stations keep programs like Marketplace on the air. But for Marketplace to continue to grow, we need additional investment from those who care most about what we do: superfans like you.

Your donation as little as $5 helps us create more content that matters to you and your community, and to reach more people where they are whether thats radio, podcasts or online.

When you contribute directly to Marketplace, you become a partner in that mission: someone who understands that when we all get smarter, everybody wins.

View original post here:
Pet food makers look to tap the alternative meat market - Marketplace

Read More...

University of Birmingham signs up for strategic research vision in India – University of Birmingham

February 25th, 2020 5:43 pm

University of Birmingham Vice-Chancellor Professor Sir David Eastwood with representatives of partner organisations at the signing ceremony in Delhi.

Experts at the University of Birmingham will work with partners in India across education, healthcare, genetic engineering and sports science.

Vice-Chancellor Professor Sir David Eastwood signed a range of Memoranda of Understanding (MoU) with the Universitys partners at a special signing ceremony in Delhi.

The agreements form a key part of the Universitys strategic vision to continue building meaningful education and research partnerships in India.

Professor Sir David Eastwood signed MoUs with:

The University of Birminghams collaborative research output with India partners has almost doubled over the last five years. We currently have over 40 joint research projects of outstanding quality, commented Professor Sir David Eastwood.

We are a global university with a civic heart and a long, illustrious relationship with India. Signing these exciting new agreements with partners in areas such as health, transport and environment gives us a great opportunity to further contribute to Indian society as we continue to forge meaningful research and education partnerships in India.

The University and ICGEB plan to work together on multidisciplinary research including immunity and infection, as well as projects tackling human diseases, compound screening for identifying autophagy modulators, and exchanges of students and staffs across relevant projects.

Working in partnership with CIPLA, University experts will develop healthcare Continuous Professional Development (CPD) programmes.

Researchers at PDPU and Birmingham will continue working on the joint India-H2O project, which is developing, designing and demonstrating high-recovery, low-cost water treatment systems for saline groundwater, as well as domestic and industrial wastewaters. The partners will also identify new research opportunities.

The agreement with Technofin will see the partners working together on a bid to provide rail research and consultancy to the Dedicated Freight Corridor Corporation of India Ltd., to support the establishment of a Heavy Haul Research Institute. They will also develop other infrastructure-related research.

Manipal engineering students will be able to join Birmingham courses in Civil Engineering, Computer Science and Engineering, Electrical and Electronics Engineering, Mechanical Engineering and Mechatronics Engineering - after completing two years of study in India, graduating with degrees from both universities.

University experts will work with Inspire Institute of Sport to develop bespoke distance-learning and blended CPD programmes for the development of the Institutes staff, as well as developing scholarships for postgraduate study in sports science. The MoU is an outcome of the India-UK Sports Alliance set up by the UK Governments Department for International Trade to drive collaboration in sports between the two countries.

Crispin Simon, Her Majestys Trade Commissioner for South Asia, UKs Department of International Trade and British Deputy High Commissioner, Mumbai and West of India, said: I am delighted that the University of Birmingham is strengthening its presence in India across education, healthcare, genetic engineering and sports science. The UK government has played an instrumental role in establishing their partnership with Inspire Institute of Sport, and we will continue to support their work in India.

I am also glad that Professor Tim Cable from the University of Birmingham has made significant contributions to the Indian-UK Sports Alliance organised by the UK government, to bring together influential individuals in both countries to help drive collaboration. I look forward to his continued participation.

See the article here:
University of Birmingham signs up for strategic research vision in India - University of Birmingham

Read More...

More Cell and Gene Therapy Facilities in the Hundreds are Needed – Genetic Engineering & Biotechnology News

February 25th, 2020 5:43 pm

The bioindustry will require more cell and gene therapy plants, says an expert, who says the facilities of the future must be automated, scalable, and flexible.

The number of cell and gene therapies entering clinical development has increased significantly in recent years. According to the Alliance for Regenerative Medicines (ARM) there are 1,066 such therapies in trials at present1, which is a 32% increase on the number of studies in 2014. But the surge in clinical activity has not been matched by an increase in production capacity says Darren Dasburg, a cell and gene therapy-focused consultant.

Hundreds of facilities will be needed to manufacture the treatments that are in play now, he said, adding that if you factor in the plants needed to make viral vectors that could exceed a thousand facilities.

The good news, Dasburg says, is that these facilities are more like labs than traditional large biopharmaceutical plants.

Viral vector capacity is critical to the cell and gene therapy sector. Vectors are hollow viruses used to insert genetic material into cells, both cells used in protein expression and cells used therapeutically. Various organisations have voiced concerns about industry capacity to make vectors. In 2018, for example, the Alliance for Advanced Biomedical Engineering said the scarcity of viral vectors could hamper expansion2. Since then the situation has improved, but it has not been resolved3. While viral vector production capacity in the contract services sector has increased, the expansion is still falling short of demand.

Partly this is because of the complexity of making the vectors, according to Dasburg.

Most viral vectors are produced using adherent manufacturing technologies which are expensive to operate, he explains. A vial of just 20 million cells can cost $2030K because it is so challenging to make.

To bring down costs, vector capacity still needs to increase, continues Dasburg, who predicted that biopharma will continue to rely on CDMOs for the foreseeable future.

Cell and gene therapy manufacturing is still a young industry. Biopharma is still figuring out what the ideal production facility should look like.

Building for flexibility and multipurpose manufacturing is important, Dasburg says, noting that explaining CDMOs and IP holders need to understand they are attacking rare genetic diseases and ailments where the therapy might be a third-line treatment. The numbers are often quite lower, and the treatments can be one and done. All meaning the companies of the future will be attacking many more areas of need.

In terms of technology, all cell and gene therapy facilities should feature sufficient isolator capacity, Dasburg says. Isolators are probably the number one investment to make. Too many people are trying to work five people in full dress in a small room attempting to manufacture in a hands-on traditional way when isolation and automation could help immensely.

Dasburg pointed to benchtop platforms capable of processing a single CAR-T patients treatment as an example of an innovative approach being used. These can be arranged in an array within a single ballroom-like facility providing 100% containment going from leukapheresis bag to treatment bag without any human intervention.

References1. alliancerm.org/wp-content/uploads/2020/02/CBX-Meeting-7-Feb-2020-FINAL.pdf2. aabme.asme.org/posts/virus-shortage-for-cell-therapies-creates-engineering-opportunity3. http://www.genengnews.com/insights/gene-therapy-dollar-is-waiting-on-viral-vector-dime/

Link:
More Cell and Gene Therapy Facilities in the Hundreds are Needed - Genetic Engineering & Biotechnology News

Read More...

Viewpoint: We can sustainably feed 10 billion people. Here’s how CRISPR and GMO crops can help – Genetic Literacy Project

February 25th, 2020 5:43 pm

Agriculture is responsible for the production of a quarter of the total human-generated greenhouse gases. Growing food also uses about 70 percent of the water available to us. Moreover, agriculture (especially meat production) is the single most significant driver of deforestation and biodiversity loss. Food production is detrimental to the health of the planetbut it doesnt end there. Once the food reaches plates, poor-quality diets cause malnutrition, claiming more lives than tobacco, drug and alcohol combined.

Search for malnutrition online and you will see pictures of frail and sick children. But along with stunting, wasting, vitamin and mineral deficiency, malnutrition also includes overweight, obesity and other diet-related illnesses. Yes, 1 in 9 people around the world go to sleep hungry, but nearly 2 billion adults are also overweight or obese. As such, more than one-third of the world population suffers from at least one form of malnutrition.

With the climate and biodiversity crises, and the global public-health crisis in the form of malnutrition, we must find a healthy and environmentally sustainable diet to feed the growing population. In 2019, the EAT-Lancet Commission brought together leading experts in nutrition, health, sustainability and policy to recommend ways to transform the global food system to achieve a healthy and sustainable diet.

The EAT-Lancet report recommends that planetary health diets to feed 10 billion people by 2050 requires cutting down meat consumption by half and eating twice as much as fruits, vegetables, beans and nuts. Despite recognizing the need to make healthy food affordable for the poor, the EAT-Lancet Commission didnt review the cost and affordability of the ideal diet. Therefore, in a recent global study, scientists reviewed prices for nearly 750 food items to calculate the value of healthy and sustainable diets in 159 countries.

The research, published in Lancet Global Health, shows that many people in low and lower-middle-income countries are too poor to afford EAT-Lancets ideal diet. EAT-Lancet says that we would need to eat twice as much as many fruits and vegetables, and get more protein and fats from plant-source foods. However, the new study found that fruits, vegetables, beans and nuts are the most expensive items of the ideal diet accounting for half of its total price.

Shifting foodsystems

A key challenge of the 21st-century is to change our food system to produce a healthy diet that is both economically and environmentally sustainable. As EAT-Lancets ideal diet isnt affordable for much of the worlds low-income population, authorities must make several parallel interventions to tackle global food inequality.

Lower food prices and higher earnings would give poor people more purchasing power. We must also find cheaper, nutritious food alternatives that are affordable and accessible to people living in low-income areas. I believe that biotechnology has the power to lower the cost of locally and globally grown food, making the ideal diet economically viable to those that need it the most.

One problem is the lack of available, affordable options, which partly stems from decreasing agrobiodiversity. Just three crops (rice, wheat and corn) provide over half of the plant-derived calories worldwide. Shifting calories away from the starchy staple foods towards more nutritious fruits, vegetables and other protein-sourced food remains a significant challenge in meeting EAT-Lancet targets. Grand challenges require great technological solutions, and genetic engineering technology is among the most powerful tools at our disposal.

Power of biotechnology

Biotechnology can improve agrobiodiversity and provide more locally-grown food options for people in low-income areas. One way to do this would be to make inedible plants into a good source of nutrition and calories. Take cottonseed, for example, which has the potential to be a cheaper alternative to nuts. Cottonseeds are highly nutritious, containing oils and proteins in abundance, but many low-income cotton farmers cant eat cottonseeds because they produce toxins called gossypol.

Now, scientists have engineered cotton plants to remove the toxin, making cottonseeds safe for us to eat. And recently, the U.S. Food and Drug Administration approved genetically modified (GM) cottonseed for human consumption. Biotech cottonseed can act as an excellent alternative dietary source in low-income regions, where people struggle to meet the costs of the ideal diet recommended by EAT-Lancet.

Genetic engineering can also enable widespread cultivation of local plants. The groundcherry plant in its native form has a wild, sprawling growth habit which causes its fruits to drop to the ground while still small. Difficulties in cultivating the wildcherry mean its an orphan plant. However, scientists used genetic engineering to improve wildcherrys undesirable traits, including the plants weedy shape, flower production and fruit size. Now there are hopes for large-scale cultivation of genetically engineered groundcherry, which is native to Central and South America.

Millions of children and adults around the world suffer from micronutrient deficiencies, and biotechnology can also help fortify current crops to improve their vitamin and micronutrient contents. For example, scientists have recently developed biofortified cassava, which has higher zinc and iron contents than regular cassava. The biofortified cassava may one day prevent illnesses related to iron and zinc deficiencies.

Golden Rice is perhaps the prime example of a biofortified cropconventional rice that is genetically engineered to produce the vitamin A precursor beta-carotene. Golden Rice, acting as a source of vitamin A, can address vitamin A deficiency that blinds and kills hundreds of thousands of children every year. After a rigorous biosafety assessment in the Philippines, the Department of Agriculture-Bureau of Plant Industry found Golden Rice to be safe as conventional rice. Golden Rice regulation application is under review in Bangladesh, as well. This biofortified crop can provide much-needed micronutrients, taking the everyday staple food further to meet peoples dietary requirements in the poorest regions of the world.

Economic benefits

Improved agrobiodiversity and availability of local food varieties, enabled by biotechnology, will bring down the cost of the ideal diet, reducing food inequality. But GM technology also has the power to lift people out of poverty and increase the spending power of the low-income communities in developing regions.

Higher farm productivity, especially in low-income areas, can lower food prices. A meta-analysis of studies published after 1995 found that adopting GM technology has widespread benefits, including economic gains for farmers that grow GM crops. The meta-analysis found that GM technology increases crop yields by 21 percent. Some GM crops are engineered to be more resistant to pest damage, which helps achieve higher yields, for example.

The meta-study also found that GM crops require 37 percent less pesticide, which reduces pesticide costs by 39 percent and helps spare the environment. Even though GM seeds are more expensive than non-GM seeds, savings in pest control and pesticide use mean that farmers adopting GM crops enjoy 68 percent more profit. Therefore, GM crops can increase farmers spending power, which is excellent news for the quarter of the worlds working population employed in agriculture . More importantly, the yield and profit from GM crops are higher in developing countries than in developed countries.

If adopted widely, genetic engineering technology will bring us closer to meeting the EAT-Lancet dietary targets, which will help us protect the environment, public health, and reduce inequality.

Rupesh Paudyal holds a PhD in plant science and covers agriculture and the environment as a freelance writer. Visit his website and follow him on Twitter @TalkPlant

See more here:
Viewpoint: We can sustainably feed 10 billion people. Here's how CRISPR and GMO crops can help - Genetic Literacy Project

Read More...

Texas coronavirus cases climb to three in San Antonio – The Texas Tribune

February 25th, 2020 5:43 pm

Two more cases of the new strain of coronavirus have been confirmed at the San Antonio military base where some evacuees from a cruise ship were quarantined Monday, the Centers of Disease Control and Prevention said at a press conference Friday. This brings the number of confirmed Texas cases of the strain named COVID-19 to three.

The two evacuees were among 329 Americans repatriated against the CDC's recommendation after disembarking from the Diamond Princess off of Japan. Another 16 cruise ship evacuees quarantined in California and Nebraska have also been confirmed to have coronavirus.

"[The passengers] are considered at high risk for infection, and we do expect to see additional confirmed cases of COVID-19 among the passengers," said Nancy Messonnier, director of the National Center for Immunization and Respiratory Diseases, during the press conference.

There are also several Americans hospitalized in Japan who are "seriously ill," she said.

The first Texas case was confirmed Feb. 13 when one of 91 Americans evacuated from the Hubei province of China, the epicenter of the outbreak, was hospitalized. The remaining 90 Americans were released from the San Antonio base Thursday because they showed no symptoms after a 14-day quarantine.

The World Health Organization declared COVID-19 a public health emergency by last month. According to the latest CDC report, there are over 75,000 confirmed cases worldwide, and the death toll has surpassed 2,000. But outside of China, there have been only three fatalities, and none in the U.S.

The total number of confirmed U.S. cases is 34. However, the CDC makes a distinction between cases among repatriated Americans and all other U.S. cases, as the former aren't an accurate representation of how the virus is spreading within the country, according to Messonnier.

"We don't yet have a vaccine for this novel virus, nor do we have a medicine to treat it specifically," Messonnier said.

The goal now is to slow the introduction of the virus into the U.S. to buy time to prepare the community for more cases and possibly sustained spread, she added.

Two elderly Japanese passengers aboard the Diamond Princess died after testing positive for the virus, Japan's health minister said Thursday.

Researchers at the University of Texas at Austin are working on a vaccine, and a Houston-based genetic engineering company announced this week it finished developing one. However, the Food and Drug Administration has not yet approved a vaccine.

Disclosure: The University of Texas at Austin has been a financial supporter of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in the Tribune's journalism. Find a complete list of them here.

Link:
Texas coronavirus cases climb to three in San Antonio - The Texas Tribune

Read More...

Confused About Obesity, Supplements and Organic Food? Here’s A Handbook For Busting Nutrition Myths – American Council on Science and Health

February 25th, 2020 5:42 pm

The internet can be a confusing place. A five-minute Google search for nutrition advice is perhaps the best illustration of this fact. Allow me to demonstrate with a classic example. Do GMO crops cause cancer?

Most GMOs are designed to be sprayed with Monsantos Roundup herbicide Glyphosate, the active ingredient in Roundup, is classified as a class 2A carcinogen by the International Agency for Research on Cancer ...

Or this:

Science has been studying cancer for a long time, and it has come to a few conclusions. One of which is that there are precious few ways to prevent cancer, and avoiding GMOs is not one of them.

The first statement was written by an anti-biotechnology activist with a history of fabricating fears about genetic engineering, the second by a biochemist with 30 years of research experience. Nonetheless, the average consumer or athlete may not know whom to believe at first glance. Faced with this contradictory but seemingly authoritative commentary, what do you do if you really want to know if GMOs boost your cancer risk?

The solution is simple, if not always easy to apply: turn to the experts and think critically about everything you read. To make that task a bit easier in practice, nutrition scientist David Lightsey has produced a helpful handbook to guide curious consumers through the morass dietary nonsense they'll inevitably encounter online: The Myths About Nutrition Science (TMNS).

A food and nutrition science advisor to QuackWatch, Lightsey has spent 31 years separating evidence-based information from plain old nonsense. His book, at just over 200 pages, will arm readers with a basic understanding of many perennially important nutritional issueseverything from obesity and supplements to GMO crops and pesticidesand a useful immunization against the junk science peddled online, what Lightsey calls the quagmire of misinformation which is so pervasive in this area.

This book would have been enormously helpful to me as a budding science journalist a decade ago, but anybody looking for sound nutrition information will get something out of TMNS.

The useless media and health news

Arguably the best part of TMNS is its takedown of mainstream health reporting. Citing the now classic 2005 study by physician John Ioannidis, Lightsey begins by pointing out that the bulk of medical research published today is simply incorrect. Eager to publish flashy results in top-tier science journals and desperate for grants (the lifeblood of any working scientist), many academics have resorted to cutting corners to get the results they know will attract attention, and thus more research funding.

If bona fide experts get so much wrong, Lightsey asks, can a journalist with little or no science background accurately assess what he or she is reporting on? The answer is usually no, unfortunately. Reporters don't have to be crippled by scientific illiteracy; a dedicated journalist can correct their knowledge deficit by doing some homework before writing a story. The real problem is, few of them do.

Instead, reporters more or less copy their stories from press releases universities distribute to promote research conducted by their faculty. Lightsey cites a 2015 study, for instance, which found that just over 85% of 312 medical news stories were derived from a press release or some other secondary source.

This is sloppy reporting, pure and simple. But science by press release has more lasting consequences: it exaggerates a study's results and fails to contextualize them among the much larger body of research on the topic in question. This is one of the primary reasons ACSH has caught just about every mainstream media network irresponsibly reporting, for example, that 95% of baby food is contaminated with heavy metals.

Misinformation is everywhere

This is a recurring theme throughout Lightsey's book. Whether it's a mainstream reporter, a supplement salesman at the gym or a celebrity athlete, nobody's entitled to our trust when it comes to nutrition. That's not because these sources of information are inherently unreliable, although they often do peddle nonsense. The real reason is that informed consumers should make decisions that comport with the available evidence, and not based on the conclusions of a single study or the recommendations of Tom Bradyno matter how many Super Bowls he's won.

Returning to our opening point above, Lightsey pithily sums things up:

Nutrition 'science' has become so contradictory that one must learn to take every new 'study' which declares to enlighten us about some purported nutritional health threat or benefit with a large grain of salt.

Excerpt from:
Confused About Obesity, Supplements and Organic Food? Here's A Handbook For Busting Nutrition Myths - American Council on Science and Health

Read More...

Protein Expression Market size, leaders, segment analysis and future scope scrutinized in the new analysis – WhaTech Technology and Markets News

February 25th, 2020 5:42 pm

North America has been the largest market for protein expression, with the U.S. as the larger contributor to the regional market as compared to Canada.

The protein expression market valued at $1.4 billion in 2016, and during the forecast period, it is expected to grow at an 11.7% CAGR, generating revenue of $3.0 billion by 2023. The key drivers of the market are technological advancements, growing life sciences sector, and increasing chronic disease prevalence, funding for protein-based research, and geriatric population.

Protein expression is a collective term for ways in which proteins are synthesized, modified, and regulated in living organisms.

Download sample copy of this report at@bit.ly/38YmQAq

A prominent trend in the protein expression marketis the increasing research and development (R&D) activities on recombinant proteins. The technologies that are used to produce recombinant proteins, such as gene cloning and genetic engineering, have revolutionized the life sciences sector and enabled the production of biopharmaceuticals at an industrial scale.

Their production on such a large scale has led to their application in disease diagnosis and treatment. Many pharmaceutical companies are focusing on the production of recombinant proteins and their expression systems to support the drug discovery process and develop biotherapeutics.

The protein expression market is segmented by region, system, end user, product and services, and application.

Based on system, the categories are algal-based, prokaryotic, cell-free, mammalian cell, yeast, and insect cell expression systems. In 2016, prokaryotic expression systems registered the largest share as they are comparatively cheaper than other expression systems, such as insect cell and mammalian systems.

In addition, the shorter protein synthesis time of the prokaryotic expression system, as the bacteria multiply and grow rapidly in these systems, giving a higher yield, promotes their adoption.

Pre-AccessInquiry at@bit.ly/2SVOV5E

North America, Middle East & Africa, Europe, Latin America, and Asia-Pacific (APAC) are the subdivisions of the region segment of the protein expression market. In 2016, the market was dominated by North America, followed by Europe.

Even though during the forecast period, the market is expected to be led by North America, the fastest growing market would be APAC. This may be attributed to the increasing geriatric population, rising R&D funds, improving per capita income, and rising prevalence of chronic diseases in the region.

Therefore, the market for protein expression is set to experience remarkable growth during the forecast period owing to an increase in drug discovery and development and growing prevalence of several types of diseases.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more here:
Protein Expression Market size, leaders, segment analysis and future scope scrutinized in the new analysis - WhaTech Technology and Markets News

Read More...

Healthy-ish French Fries Are Now a Thing Thanks to Genetic Redesigning – Observer

February 25th, 2020 5:42 pm

With Calyxt making fried foods healthier, maybe celebs will actually eat them instead of just posing with them. Rich Polk/Getty Images for The Weinstein Company

Eat up, America. Your favorite standby comfort foodthose slightly greasy, salted-just-right French fries that have thrown many a dieter off the straight and narroware now healthy. Or at least healthier than they ever have been, thanks to food-tech disruptor Calyxt (pronounced Kay-Lix with an aspirated t at the end) and its breakout vegetable oil, which is designed with less saturated fat and more healthy oleic acid than typical unmodified frying oils.

I first stumbled across Calyxts healthy frying oil at the most unlikely of places: the Minnesota State Fair,a 320-acre mecca of unhealthy eating, butter sculptures, live farm animal births and other assorted curiosities.

SEE ALSO: How Blue Apron Became a Massive $2 Billion Disaster

Any good Minnesotan worth his weight in walleye, even those of us like me who have lived all over the world, will always make a point to come back to our native Land of 10,000 Lakes in late August, in part so we can take in one of the states few months of non-sub-zero temperatures, but also because the second half of August is precisely when we can visit the two-week affair known among locals as the The Great Minnesota Get-Together. Its the largest of its kind in the country, and last years attendance drew in over two million visitors, meaning over a third of all Minnesotans took a day out of their lives to join in on the perennial celebration.

At last years gathering, word was spreading quickly that the Ball Park Caf, a long-time state fair staple, known for its famous beer selection, burgers and garlic fries, had switched to Calyxts healthier vegetable oil for all of its frying needs. Given that the fair happened to fall just as I was several weeks into one of my many concerted efforts to finally get back in shape, I was intrigued.

I was expecting the fries I ordered to taste somehow artificial or rubbery, as do many healthy versions of other foods, but the flavor and consistency of the Calyxt-fried Freedom Fries was exactly as one might expect from a normal bath of hot oilcrispy and yummy. Decadence never tasted so good.

Several weeks after the fair, I looked up the company behind this healthy oil and scheduled a meeting with Calyxts communications head, Trina Lundblad and company CEO Jim Blome. We decided to meet at their offices, a sleek, ultra-modern building in a Minneapolis suburb, overlooking a large swath of prairie grass and pristine crop rows.

The Calyxt headquarters have a definite Silicon Valley feel. Were not an ag company; were a tech company that is applying its IP to the ag sector, said company spokeswoman and communications head Trina Lundblad. Courtesy of Calyxt

For the next several hours that I spent touring the Calyxt headquarters, I came to realize that I was not just visiting, contrary to my expectations going in, another food-based CPG company simply riding the wave of a popular new frying oil with a healthy twistI was at ground zero of the tech revolution in agriculture, where genome editing is revolutionizing the nutritional attributes of the foods we, as humans, will need to continue as a species in the years and centuries to come.

If that sounds like a big deal, its because it is.

Calyxt describes its oil, the product of an improved soybean plant, as having the heart-healthy fat profile of olive oil without the distinctively earthy aftertaste that is fine for spaghetti, but less so for waffles or fried chicken. By using a breakthrough gene-editing technology, Calyxt is engineering an entirely new set of processes for improving the genetic profile for many staples of the nutritional supply chain without introducing transgenic, foreign properties into the mix; Calyxts technology stands out in that it is simply accelerating and improving upon what nature would have probably gotten around to eventually on its own, only several millennia later.

Importantly, the process used by Calyxt, which relies on DNA-cutting enzymes that thankfully go by the abbreviation TALEN (transcription activator-like effector nuclease), sidesteps much of the public and regulatory outcry often associated with traditional GMOs (genetically modified organisms), in which an organisms genetic makeup has been modified in a laboratory using transgenic technology that combines, in a sort of Frankenstein-esque way, plant, animal, bacterial and virus genes that do not occur in nature or through traditional crossbreeding methods.

Calyx, which is a publicly-traded company on the NASDAQ, is improving upon the farm to table fever, by starting upstream.

Way upstream.

Calyxts unique engineering process begins in the high-tech labs on the top floor of the companys headquarters, where a team of scientists reconfigure gene molecules on large computer monitor screens before instructing robotically controlled laboratory pipettes to do their thing. Later, embryonic plant cells are transferred to petri dishes that deliver the customized TALENs, which are then bathed in stimulating hormones and left to grow until they become big enough to see if the edits made upstream in the top floor lab were successful.

Plants that meet the designer teams original specs get pampered in high-tech temperature-regulated nurseries before later graduating to a greenhouse or to the small outdoors plot trials that abut the Calyxt headquarters. From the top performing plants, Calyxt begins developing seed banks that will eventually be sold to farmers.

But that is only the beginning. Its here, at this leg of the business, where Calyxt is positioning itself for long-term, paradigm shifting growth at the crossroads of technology and agriculture.

Jim Blome, the CEO of Calyxt, grew up in a family farm in central Iowa. Today, he leads a company that is playing a major role in defining the future of food on a global scale. Courtesy of Calyxt

Unlike most biotech companies that play in the broader competitive landscape of gene-editing, Calyxt is unique in that it is vertically integrating, contracting with farmers across the Midwest to grow its gene-edited, high oleic soybeans. Earlier this month, the company achieved an important milestone, having successively contracted 100,000 soybean acres with U.S. farmers, more than doubling the size of its planted acres from the previous year. Calyxt CEO Jim Blome lauded the achievement stating that 100,000 contracted acres will support market demand for our high oleic soybean oil.

Calyxts scientists design gene-editing molecules on computer screens, then use robots to build them using a set of DNA-cutting enzymes called TALENs, which are later transferred to petri dishes for analysis. Courtesy of Calyxt

After the growing season, just a few weeks after the Minnesota State Fair wraps up, Calyxt exercises its contracts to buy back the beans from the farmers at a premium to market prices and crushes them to make its healthy, french fry-friendly oil, which it is currently shipping across the country to food services companies and restaurant chains.

Farmers love the higher-than-market commodities prices Calyxt agrees to pay them. The food services sector loves the healthy aspects of the Calyxt end-product, which also has a reuse rate far more efficient than other oils on the market. And Calyxt loves sitting in the middle of both the supply and distribution chains.

I have spent my life in agriculture, and there is nothing as revolutionary happening around genome editing as what we are doing at Calyxt, added Blome, who previously served as the president and CEO of the North American Crop Science division of Bayer, the German multinational pharmaceutical and life sciences juggernaut. We are developing a foundation for the future of global agriculture through precision plant breeding and advanced analytical tools to solve complex challenges with system-based approaches. Tillable land is growing increasingly scarce, populations are growing and the earth is warming, and frankly, we arent ready for what this will mean even five or 10 years down the road.

What we are doing at Calyxt is harnessing the technology that will enable the entire global nutritional and industrial supply chain to adapt to these seismic changes underfoot. And were doing it in a responsible, ethical manner, that brings new opportunities to U.S. farmers, added Blome.

The Calyxt chief isnt simply talking about healthier frying oils, there is a much, much bigger play in the offing: Calyxts technology can be harnessed to address some of the most pressing concerns across all of food and nutritionfrom removing the allergens from nuts and peanuts, to designing better cereal plants, such as wheat, that not only deliver better yields but also address common allergies and afflictions like gluten intolerance. Tubers, tree fruits, CBD productsthe list of potential applications for Calyxt genome-editing is nearly endless.

Where high-tech meets agriculture. Calyxt researchers and plant scientists use state-of-the-art aeroponics growing facilities to iterate on plant-based genome editing. Courtesy of Calyxt

Chris Neugent, a veteran food marketer and former CEO of Post Consumer Brands, the maker of everything from Oreo Os to Grape-Nuts, sits on the board of Calyxt, bringing mission-critical consumer marketing and story-telling gravitas to a company known best for its high-tech bioengineering.

If the Calyxt story was a book, then you could say we are still in the first chapter, probably still on page one. Our work with smarter, healthier soybean oilsas groundbreaking as it isis still proof of concept. As we scale our business and begin adding more products, the market will begin to see us not as the healthier french fry guys but as a company that is revolutionizing next-generation nutrition in agriculture, observed Neugent. We are literally laying track for the biggest agricultural revolution since the transformation of human societies from hunting and gathering to farming. Its that big.

This Second Agricultural Revolution Neugent is alluding to envisages a not-so-far-off future in which Calyxt is redesigning crops to better withstand the massive changes underfoot caused by global warming, over-population and other seismic shifts affecting the future of food.

A young soybean plant flowers inside the Calyxt high-tech laboratory facilty. Courtesy of Calyxt

Like any industry that is shaking up the status quo, Calyxt is beginning to encounter its share of crosscurrents. So far, at least, U.S. regulators seem to be of the opinion that as long as Calyxt is making genetic alterations that could have conceivably occurred naturally, as opposed to other transgenic techniques used in GMOs, no special regulation is needed.

Other incumbent seed engineering companies have dabbled in the high oleic soybean space, but for the most part, they have come at the challenge through a more conventional gene-editing approach, which mixes in organisms that do not naturally conjoin outside of a laboratory, necessitating additional layers of regulatory safeguards.

Calyxt is using high-tech genome editing to serve up healthier versions of the same delicious plant-based foods that we have eaten for decades. Courtesy of Calyxt

For now, Calyxts approach doesnt require any additional oversight or specific product labeling, nor do company executives feel that any will be required at any point in the foreseeable future. The 2018 USDA-released GMO labeling requirements defines bioengineered foods as those containing detectable genetic material that has been modified through lab techniques that cannot be created through conventional breeding or found in nature. As a result, Calyxt is not subject to any additional regulatory or labeling requirements, which is allowing the company to forge ahead on multiple fronts. The company is already engaged in early experimentation with genome edited wheat plants, and it has scores of other applications in development.

For now, Calyxt is a still a small company, but one poised to make a big impact on the global food market.

However, for most of usat least those of us that just like to be able eat French fries from time to time and not feel too bad about it the next dayCalyxt is performing an equally important service on par with helping prepare global food sourcing for the impacts of climate change; they are giving us peace of mind the next time we hit the state fair, or anywhere else where Calyxt-fried French fries are being served.

See original here:
Healthy-ish French Fries Are Now a Thing Thanks to Genetic Redesigning - Observer

Read More...

Coronavirus was not genetically engineered. Instead it is the first Infodemic – TechStartups.com

February 25th, 2020 5:42 pm

The spread of coronavirus seems to be slowing down in China as the country continues to put proper measure in place to slowdown the spread of the disease. However, the virus outbreak in Iran, Italy, and South Korea are raising fears of a broader epidemic. The coronavirus (COVID-19), caused by SARS-CoV-2 started in Whuan China started in December 2019. To date, coronavirus has claimed 2,701 human lives and wreck havoc to global markets.

As of 25 February 2020, around 80,149 cases have been confirmed, including in all provinces of China and more than two dozen other countries. Of these, 11,569 cases were classified as serious. There have been 2,701 deaths attributable to the disease, including 38 outside mainland China, surpassing that of the 2003 SARS outbreak.

As the virus spread around the world so are the rumors about the origin of the virus. Weve written many stories about the virus ranging from Chinese scientists arguing that the the virus originated from Chinas Wuhan laboratory. Some media outlets also pointed to comments from Chinas Presidentabout the need to contain the coronavirus and set up a system to prevent similar epidemics in the future. President Xi said a national system to control biosecurity risks must be put in place to protect the peoples health because lab safety is a national security issue.To add to the suspicion, NY Post also pointed toa newly release directive from Chinese Ministry of Science and Technology titled: Instructions on strengthening biosecurity management in microbiology labs that handle advanced viruses like the novel coronavirus.

The problem, however, is these news storieshave very little scientific merit. According to a new study published in ScienceDirect titled: Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event, their findings show that theCOVID-19 is 96 percent similar to the bat virus RaTG13. The 2019-nCoV although closely related to BatCoV RaTG13 sequence throughout the genome (sequence similarity 96.3%), shows discordant clustering with the Bat_SARS-like coronavirus sequences, the authors said.

The study concludes with the statement: The levels of genetic similarity between the 2019-nCoV and RaTG13 suggest that the latter does not provide the exact variant that caused the outbreak in humans, but the hypothesis that 2019-nCoV has originated from bats is very likely. Their conclusion supports the widely accepted claim that coronavirus originated from Whuan meat market where bats are snakes were sold for food.

The question is, what do we make of the study published by Chinese scientists in The Lancet?The wider scientific community, upon seeing the paper, were also less than impressed with the speculations and conclusions drawn by the Chinese scientists. The scientist at the forefront of an international effort to track the deadly coronavirus outbreak shot down claims about the diseases origins, including that it escaped from a Wuhan laboratory after being genetically engineered.Trevor Bedford, of the Fred Hutchinson Cancer Research Center in Seattle, said:There is no evidence whatsoever of genetic engineering that we can find. He made the statement at the American Association for the Advancement of Science meeting in Seattle. The evidence we have is that the mutations (in the virus) are completely consistent with natural evolution.

Finally, on February 2, the World Health Organization (WHO)called the new coronavirus a massive infodemic, referring to an overabundance of informationsome accurate and some notthat makes it hard for people to find trustworthy sources and reliable guidance when they need it.

Due to the high demand for timely and trustworthy information about 2019-nCoV, WHO technical riskcommunication and social media teams have been working closely to track and respond to myths and rumours.Through its headquarters in Geneva, its six regional offices and its partners, the Organization is working 24 hours aday to identify the most prevalent rumors that can potentially harm the publics health, such as false preventionmeasures or cures. These myths are then refuted with evidence-based information. WHO is making public healthinformation and advice on the 2019-nCoV, including myth busters, available on its social media channels (includingWeibo, Twitter, Facebook, Instagram, LinkedIn, Pinterest) and website, WHO said.

Read the original post:
Coronavirus was not genetically engineered. Instead it is the first Infodemic - TechStartups.com

Read More...

34 years with a new heart and counting – MDJOnline.com

February 25th, 2020 5:41 pm

Whenever Harry Wuest has a doctors appointment in northern Atlantas hospital cluster dubbed Pill Hill, he makes sure to stop by the office of Dr. Douglas Doug Murphy for a quick chat.

And Murphy, unless hes tied up in the operating room, always takes a few minutes to say hello to his former patient. Remember when ... ? is how the conversation typically starts, and its always tinged with laughter, often joyful, sometimes bittersweet.

Its a reunion of two men who shaped a piece of Georgias medical history.

Almost 35 years ago, Murphy opened the chest of Wuest and sewed in a new heart, giving him a second shot at life. Wuest was the third heart transplant patient at Emory University Hospital.

Tall, lanky, with short curly hair and a quiet demeanor, Wuest is the longest-surviving heart transplant recipient in Georgia and one of the longest-surviving in the world. The 75-year-old accountant still plays golf twice a week and only recently went from working full-time to part-time. My heart is doing just fine, he says.

Murphy is now the chief of cardiothoracic surgery at Emory Saint Josephs Hospital and still in the operating room almost every day. He has moved on to become the worlds leading expert in robotically assisted heart surgery.

Harry Wuest is originally from Long Island, New York. After a stint in the Air Force, he moved to Florida to work and go to school. He wanted to become a physical education teacher. Then, in 1973, he fell ill. It started with some pain on his left side. He didnt think much of it, but when he got increasingly winded and fatigued, he went to see a doctor.

Several months and numerous specialists later, he received the diagnosis: Cardiomyopathy, a disease of the heart muscle that can make the heart become enlarged, thick and rigid, preventing it from pumping enough blood through the body.

They didnt know how I got it, says Wuest, sitting back in a brown leather armchair in the dark, wood-paneled living room of his Stone Mountain home. Maybe it was a virus. And back then, there wasnt much they could do to treat it, except bed rest.

For the next 12 years, Wuest lived life as best as he could. He got a degree in accounting from the University of Central Florida and worked for a real estate developer. There were good days, but there were more bad days. He was often too weak to do anything, and his heart was getting bigger and bigger.

Emorys first transplant surgeon

The first successful human-to-human heart transplant was performed in Cape Town, South Africa, in 1967 a medical breakthrough that catapulted the surgeon, Dr. Christiaan Barnard, onto the cover of Life magazine and to overnight celebrity status.

This highly publicized event was followed by a brief surge in the procedure around the world, but overall, heart transplants had a rocky start. Most patients died shortly after the surgery, mainly due to organ rejection. Back then, immunosuppressive drugs, which can counteract rejection, were still in their infancy. Many hospitals stopped doing heart transplants in the 1970s.

That changed with the discovery of a highly effective immunosuppressive agent. Cyclosporine got FDA approval in 1983 and altered the world of organ transplants.

It was shortly thereafter when Emory University Hospital decided to launch a heart transplant program, but none of the senior surgeons wanted to do it. Even with the new drug, it was a risky surgery, and mortality was still high.

Its an all-or-nothing operation, Murphy says, as he sits down in his small office overlooking the grayish hospital compound. Hes wearing light blue scrubs from an early morning surgery. At 70, he still has boyish looks, with a lean build and an air of laid-back confidence. If you have a number of bad outcomes initially, it can be detrimental to your career as a surgeon, he says.

But Murphy didnt really have a choice. He remembers that during a meeting of Emorys cardiac surgeons in 1984, he was paged to check on a patient. When he returned, the physicians congratulated him on being appointed the head of the new heart transplant program. He was the youngest in the group and had been recruited from Harvards Massachusetts General Hospital just three years before.

Yeah, thats how I became Emorys first transplant surgeon, says Murphy.

He flew to California to shadow his colleagues at Stanford University Hospital, where most heart transplants were performed at the time. Back home at Emory, he put together a team and rigorously rehearsed the operation. The first transplant patient arrived in April 1985. The surgery was successful, as was the second operation less than a month later.

Around the same time, Harry Wuest wound up in a hospital in Orlando. He needed a transplant, but none of the medical centers in Florida offered the procedure. One of his doctors recommended Emory, and Wuest agreed. I knew I was dying. I could feel it. He was flown to Atlanta by air ambulance and spent several weeks in Emorys cardiac care unit until the evening of May 23, when Murphy walked into his room and said, Weve got a heart.

I could finally breathe again

The heart, as the patient later learned, came from a 19-year-old sophomore at Georgia Tech who had been killed in a car crash.

Organ transplants are a meticulously choreographed endeavor, where timing, coordination and logistics are key. While Murphy and his eight-member team were preparing for the surgery, Wuest was getting ready to say farewell to his family his wife and three teenage sons, and to thank the staff in the cardiac ward.

I was afraid, he recalls, especially of the anesthesia. It scared the heck out of me. He pauses during the reminiscence, choking briefly. I didnt know if I was going to wake up again.

The surgery took six hours. Transplants usually happen at night because the procurement team, the surgeons who retrieve different organs from the donor, only start working when regularly scheduled patients are out of the operating room.

Despite the cultural mystique surrounding the heart as the seat of life, Murphy says that during a transplant surgery, its not like the big spirit comes down to the operating room. Its very technical. As the team follows a precise routine, emotions are kept outside the door. We dont have time for that. Emotions come later.

Waking up from the anesthesia, Wuests first coherent memory was of Murphy entering the room and saying to a nurse, Lets turn on the TV, so Harry can watch some sports.

Wuest spent the next nine days in the ICU, and three more weeks in the hospital ward. In the beginning, he could barely stand up or walk, because he had been bedridden weeks before the surgery and had lost a lot of muscle. But his strength came back quickly. I could finally breathe again, he says. Before the surgery, he felt like he was sucking in air through a tiny straw. I cannot tell you what an amazing feeling that was to suddenly breathe so easily.

Joane Goodroe was the head nurse at Emorys cardiovascular post-op floor back then. When she first met Wuest before the surgery, she recalls him lying in bed and being very, very sick. When she and the other nurses finally saw him stand up and move around, he was a whole different person.

In the early days of Emorys heart transplant program, physicians, nurses and patients were a particularly close-knit group, remembers Goodroe, whos been a nurse for 42 years and now runs a health care consulting firm. There were a lot of firsts for all of us, and we all learned from each other, she said.

Wuest developed friendships with four other early transplant patients at Emory, and he has outlived them all.

When he left the hospital, equipped with a new heart and a fresh hunger for life, Wuest made some radical changes. He decided not to return to Florida but stay in Atlanta. Thats where he felt he got the best care, and where he had found a personal support network. And he got a divorce. Four months after the operation, he went back to working full-time: first in temporary jobs and eventually for a property management company.

After having been sick for 12 years, I was just so excited to be able to work for eight hours a day, he recalls. That was a big, big deal for me.

At 50, he went back to school to get his CPA license. He also found new love.

Martha was a head nurse in the open-heart unit and later ran the cardiac registry at Saint Josephs Hospital. Thats where Wuest received his follow-up care and where they met in 1987. Wuest says for him it was love at first sight, but it took another five years until she finally agreed to go out with him. Six months later, they were married.

Harry Wuest and his wife, Martha. She was a head nurse in the open-heart unit and later ran the cardiac registry at Saint Josephs Hospital. Thats where Wuest received his follow-up care and where they met in 1987. Wuest says for him it was love at first sight, but it took another five years until she finally agreed to go out with him. Six months later, they were married.

Having worked in the transplant office, I saw the good and the bad, Martha Wuest says. A petite woman with short, perfectly groomed silver hair, she sits up very straight on the couch, her small hands folded in her lap. Not every transplant patient did as well as Harry. And I had a lot of fear in the beginning. Now he may well outlive her, she says with a smile and a wink.

Wuests surgeon, meanwhile, went on to fight his own battles. Two and a half years into the program, Murphy was still the only transplant surgeon at Emory and on call to operate whenever a heart became available. Frustrated and exhausted, he quit his position at Emory and signed up with Saint Josephs (which at the time was not part of the Emory system) and started a heart transplant program there.

At St. Josephs, Murphy continued transplanting hearts until 2005. In total, he did more than 200 such surgeries.

Being a heart transplant surgeon is a grueling profession, he says, and very much a younger surgeons subspecialty.

He then shifted his focus and became a pioneer in robotically assisted heart surgery. He has done more than 3,000 operations with the robot, mostly mitral valve repairs and replacements more than any other cardiac surgeon in the world.

Heart transplants "remain the gold standard"

Since Murphy sewed a new heart into Wuest 35 years ago, there has been major progress in the field of heart transplants, but it has been uneven.

There is improved medication to prevent rejection of the donor heart, as well as new methods of preserving and transporting donor hearts.

Yet patients requiring late-stage heart failure therapy, including transplantation, still exceed the number of donor hearts available. In 2019, 3,551 hearts were transplanted in the United States, according to the national Organ Procurement and Transplantation Network. But 700,000 people suffer from advanced heart failure, says the American Heart Association.

New technologies and continued research are providing hope to many of these patients. There has been significant progress in the development of partial artificial hearts, known as Left Ventricular Assist Devices, or LVADs. They can be used as bridge devices, to keep patients alive until donor hearts are available, or as destination therapy, maintaining patients for the remainder of their lives.

Also, total artificial hearts have come a long way since the first artificial pump was implanted in a patient in 1969. The technology is promising, says Dr. Mani Daneshmand, the director of Emorys Heart & Lung Transplantation Program. But its not perfect.

Long-term research continues into xenotransplantation, which involves transplanting animal cells, tissues and organs into human recipients.

Regenerative stem cell therapy is an experimental concept where stem cell injections stimulate the heart to replace the rigid scar tissue with tissue that resumes contraction, allowing for the damaged heart to heal itself after a heart attack or other cardiac disease. Certain stem cell therapies have shown to reverse the damage to the heart by 30 to 50 percent, says Dr. Joshua Hare, a heart transplant surgeon and the director of the Interdisciplinary Stem Cell Institute at the University of Miamis Miller School of Medicine.

All of these ideas have potential, says Daneshmand. But none of them are ready to replace a human donor heart. A heart transplant remains the gold standard, because you cant accommodate the same success with a machine right now, he says.

Efforts around expanding the donor pool are really the best way to address this problem, while we wait for technology to catch up, he adds.

Besides Emory, other health care systems in Georgia that currently have a heart transplant program are Piedmont Healthcare, Childrens Healthcare of Atlanta and Augusta University Health.

Organ rejection remains a major issue, and long-term survival rates have not improved dramatically over the past 35 years. The 10-year survival is currently around 55 percent of patients, which makes long-term survivors like Harry Wuest rare in the world of heart transplants.

The United Network of Organ Sharing, or UNOS, which allocates donor hearts in the United States, doesnt have comprehensive data prior to 1987. An informal survey of the 20 highest-volume hospitals for heart transplants in the 1980s found only a scattering of long-term survivors.

In for the long haul

Being one of the longest-living heart transplant recipients is something that Wuest sees as a responsibility to other transplant patients, but also to the donors family, which hes never met. If you as a transplant recipient reject that heart, thats like a second loss for that family.

Part of this responsibility is living a full and active life. Both he and Martha have three children from their previous marriages and combined they have 15 grandchildren. Most of their families live in Florida, so they travel back and forth frequently. Wuest still works as a CPA during tax season, and he does advocacy for the Georgia Transplant Foundation. In addition to golf, he enjoys lifting weights and riding his bike.

Hes had some health scares over the years. In 2013, he was diagnosed with stage 1 kidney cancer, which is in remission. Also, he crossed paths with his former surgeon, and not just socially. In 2014, Murphy replaced a damaged tricuspid valve in Wuests new heart. That operation went well, too.

Murphy says there are several reasons why Wuest has survived so long. Obviously, his new heart was a very good match. But a patient can have the best heart and the best care and the best medicines and still die a few months or years after the transplantation, the surgeon says. Attitude plays a key role.

Wuest was psychologically stable and never suffered from depression or anxiety, Murphy says. Hes a numbers guy. He knew the transplant was his only chance, and he was set to pursue it.

Wuest attributes his longevity to a good strong heart from his donor; good genetics; great doctors and nurses; and a life that he loves. Im just happy to be here, he says.

Quoting his former surgeon and friend, he adds: Doug always said, Having a transplant is like running a marathon. And Im in for the long haul.

See the article here:
34 years with a new heart and counting - MDJOnline.com

Read More...

Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy – fox2now.com

February 25th, 2020 5:41 pm

CAMP HILL, PA (WPMT) A family in Cumberland County has turned to stem cells to treat their two-year-old son diagnosed with cerebral palsy. The only problem: stem cell treatment for the disease hasnt been approved by the FDA.

The day he was born, when he wheeled him down the hall and he was only a pound, and I started to cry and said, will he live? And he said, of course Hes only small, said Danielle Maxwell, Lances mom.

The words, hes only small, are what Lances mom and father Rob have lived by since the day he was born. The preemie, born three months early, has been through several surgeries and complications along the way. But, Lance has always been a fighter.

Lance fought so hard just to survive the beginning of life, and come home with us, said Danielle. And he is just so happy and loving and amazing.

About a year ago, Lance was diagnosed with cerebral palsy. Doctors told his family, he will never walk, talk or take care of himself.

We just dont believe that, said Danielle. We dont.

Lance receives a lot of different therapies but, his parents did not want to just stop there.

We both overwhelmingly feel, he never gave up, he never gave up on us, he never gave up on himself, said Rob. So, we owe it to him to give him the opportunity. Its really that simple, he deserves the opportunity.

Danielle began researching stem cell therapies, even speaking to doctors in countries overseas where treatment with stem cells is more readily accessible than in the U.S. The FDA has approved stem cell treatments for some conditions but not cerebral palsy. However, trials to determine the effectiveness of stem cell treatment for the disease are underway.

What weve seen is a small but real appearing improvement in motor function, said Doctor Charles Cox with University of Texas Health in Houston, began a trial in 2013 on the safety and effectiveness of banked cord blood or bone marrow stem cells in children with cerebral palsy, and is now just wrapping up the results from the trial.

The overall results of this study depend if youre a glass half full or half empty kind of person, said Dr. Cox. It is not a compelling miraculous result. Its not, Oh my God, this child was treated and look at this profound benefit.'

Because stem cell treatment for cerebral palsy is still in trial phases, its not approved treatment by the FDA. However, the Maxwells did find a doctor in Harrisburg willing to transfer stem cells from a full-term babys umbilical cord to Lance. But, since it isnt FDA approved, we were not allowed to be there to show Lance receiving the stem cells. The Maxwells are hopeful following this procedure Lance may someday walk and more importantly be able to communicate with them.

He wants to be involved, said Rob. You can tell hes trying to communicate he just cant get over that hump. We believe stem cells could be that bridge to help him move a little faster.

Danielle says it will take about six months to see if the stem cells will have any definitive benefits for Lance. But, already says shes seeing progress. She says Lance is not able to stand on his own

Visit link:
Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy - fox2now.com

Read More...

New sickle cell disease treatments are helping people live longer and giving them a higher quality of life – PhillyVoice.com

February 25th, 2020 5:41 pm

Treatment for sickle cell disease has come a long way since the 1970s when the life expectancy of people living with it was less than 20 years.

People with sickle cell disease are not only living longer life expectancy is now 42 to 47 years of age but are enjoying a better quality of life, too.

"In the Philadelphia area, there has been great pediatric care for sickle cells disease and because of that people who have it are living very well," said Dr. Farzana Sayani, a hematologist at Penn Medicine.

Sayani is the director of a comprehensive sickle cell program focusing on adults living with the disease. Penn also has an active transition program for youth transitioning from a pediatric institution to adult care.

Sickle cell disease is an inherited red blood cell disorder that affects about 100,000 Americans.It is most often found in people of African or Hispanic descent.About 1 in 365 African-American babies are born with sickle cell disease, according to Sayani.

People who have the disease inherit an abnormal type of hemoglobin in their red blood cells, called Hemoglobin S, from both their mother and father.When only one parent has the hemoglobin S gene, a child will have the sickle cell trait, but usually does not develop the disease. But they may pass it on to their children.

Hemoglobin is the protein in the blood responsible for carrying oxygen to the rest of the body. Hemoglobin S causes red blood cells to become stiff and sickle-shaped. Instead of being round in shape, they look like crescent moons.

Sickle cells are sticky and can bind together, blocking the flow of blood and preventing oxygen from getting where it needs to go in the body. This causes sudden attacks of pain referred to as a pain crisis.

There are severaldifferent types of sickle cell disease.Hemoglobin SS, also known as sickle cell anemia, is the most common and most severe type of sickle cell disease.

Anemia occurs when red blood cells die at a rate faster than the body can replace them. Normal red blood cells generally live for 90 to 120 days. Sickled cells only live for 10 to 20 days. This shorter life-to-death cycle is harder for the body to sustain.

Another form,Hemoglobin SC, is not as severe as sickle cell anemia, but it can still cause significant complications, Sayani said.Other forms include Hemoglobin S0 thalassemia, Hemoglobin S+ thalassemia, Hemoglobin SD and Hemoglobin SE.

Sickle cell disease screening is a mandatory part of newborn screenings in Pennsylvania.

If the screening is positive, the family is informed and plugged into the health care system in order to receive the proper care.

If the disease is not diagnosed at birth, a blood test can confirm it at any age in which symptoms start to surface.

The severity of sickle cell disease can vary.

Each individual is affected differently, making it difficult to predict who will get what complications, Sayani said. That is why a comprehensive sickle cell program is so important.

Early signs include a yellowish tint to the skin or jaundice, fatigue and a painful swelling of the hands and feet.

"Young children with sickle cell disease may be tired, not eat very well and have delayed growth," Sayani said. "They may also develop anemia, be at greater risk of infection and start to experience pain crises."

Acute pain crises, also known as vaso-occlusive crises, can lead to long stays in the hospital to manage the crippling pain. Children with sickle cell disease also tend to experience delayed growth and puberty.

As a person with sickle cell disease grows older, the sickled red blood cells start to affect various organs, bones and joints.

This can lead to acute chest syndrome, which occurs when damaged lung tissues makes it difficult to breathe. Brain complications, including stroke, are possible.People with sickle cell disease are also prone to heart damage, eye problems, and infections like chlamydia, salmonella and staphylococcus. Chronic and acute pain is common.

There are different types of medicine that can help manage sickle cell disease.

Last year, an oral medicine was approved that makes sickle cells less likely to sickle. So was an intravenous medicine that has been shown to reduce pain crises and hospitalizations by 50%. Some people living with sickle cell disease also may need regular blood transfusions.

Hydroxyurea has also been used successfully for many years to reduce pain crises and the need for blood transfusions and hospitalizations.

Currently, blood and bone marrow transplant is the only way to cure the disease. But it is not an option for everyone because of the difficulty of finding a well-matched stem cell donor.

A related donor is best but only about a third of sickle cell patients have a donor that is related and fully-matched, Sayani said.

While these transplants have a 85% or more success rate, they also are associated with significant risks, including organ dysfunction, infection and graft vs. host disease which can be quite debilitating.

Transplants completed in children have the best results, Sayani said. But because of the risks involved, doctors only suggest it for patients with severe forms of the disease.

Early clinical trials with gene therapy are also showing promise, she added.

See more here:
New sickle cell disease treatments are helping people live longer and giving them a higher quality of life - PhillyVoice.com

Read More...

Dish Life: The Game, available now for iOS and Android, challenges you to run your very own stem cell lab – Pocket Gamer

February 25th, 2020 5:41 pm

The newly released Dish Life: The Game is described as "part Sims, part Tamagotchi". It sees you starting out as an undergraduate student, gradually rising through the scientific ranks to become a professor. You'll do this while helping your colleagues and managing the day-to-day running of your lab. It ultimately aims to showcase the laboratory as a social world, where strong relationships are key to achieving great science.

I first played developer Pocket Sized Hands' latest back in January at Pocket Gamer Connects London, and I felt it was one of the most interesting titles on the show floor. What first appeared to be a fairly straightforward educational game funded by the University of Cambridge, no less quickly revealed itself to be a surprising and layered, though still very accessible, sim with some intriguing role-playing elements.

The basic idea is that you'll work to run and expand your lab, dealing with the various complications and challenges that arise over time. Your stem cells need to be cared for, your colleagues may require your support, and you're going to have to consider a number of tough decisions that could make or break your research and friendships. You may also have to deal with things like bullying in the workplace, media controversies, and challenging ethical quandaries.

It's the sim aspects and enjoyable minutia of running a lab that makes Dish Life feel so very distinctive. Caring for your stem cells scratches that Tamagotchi itch, and managing the lab and its staff is satisfying work.

If you hear the term "educational game" and instantly switch off, know that it easily sidesteps the tedium of the genre to deliver an experience with personality to spare. There are definitely moments where your knowledge will be tested, such as the little reports you have to write, but they feel natural and dare I say it? quite fun.

It was developed in collaboration with Cambridge sociologists and stem cell scientists from the university's Stem Cell Institute, including producerDr. Lucy van de Wiel (Cambridge Department of Sociology's ReproSoc group), giving it a certain level of authenticity. The game follows on from a short film directed by Chloe Thomas and produced by Dr. Karen Jent (ReproSoc) and stem cell scientist Dr. Loriana Vitillo. I've embedded it above for you to give it a watch.

Dish Life: The Game is now available for download from both the App Store and Google Play as a free-to-play title.

Read more:
Dish Life: The Game, available now for iOS and Android, challenges you to run your very own stem cell lab - Pocket Gamer

Read More...

Brave Gourock teen battling bone cancer is in line for the Young Scot of the year award – Greenock Telegraph

February 25th, 2020 5:41 pm

AN EXTRAORDINARY teenager recovering from a fresh round of lifesaving treatment as she battles bone cancer is in line for the Young Scot of the year award.

Brave Molly Cuddihy from Gourock has won the hearts of people in Inverclyde and beyond as she fights the extremely rare Metastatic Ewing's Sarcoma.

The remarkable Clydeview Academy pupil has kept a smile on her face throughout her ordeal and raised an incredible 250,000 at a fundraising ball to help younger children battling cancer.

Earlier this month she underwent a stem cell transplant which left her in intensive care.

Her dad John, of Doune Gardens, said: "Molly is unable to physically speak at the moment because of side effects.

"She was so surprised by her nomination and over the moon.

"She found out on the day she went in for her transplant.

"It lifted her spirits and it lifts us all.

"Molly is incredible and an inspiration.

"She never feels sorry for herself, she just gets back up again and gets on with it.

"Again we have to thank everyone for their support - we are overwhelmed by the support of everyone out there.

"If love and kindness was a pill, Molly would be cured."

After the stem cell transplant Molly was in intensive care because of a series of complications caused by the treatment.

But her dad told the Telegraph: "The signs from the stem cell transplant are good."

Molly now faces a spell in isolation because the treatment has left her body with the protection of an unborn child.

Since her fundraising ball in October Molly has been undergoing treatment for cancer while also working with health chiefs to put plans in place for a special room in the Royal Hospital for Sick Children for children aged eight to 12 year olds.

Schoolgirl Molly was only 15 when she diagnosed with cancer in January 2018 and spent nearly a year in hospital.

She had bone cancer in her ribcage, which presented itself as a mass on her side but it had spread to her lungs and her spine.

She faced many months of gruelling chemotherapy and radiotherapy to blast the cancer.

The one in her spine is inoperable and has to be treated with radiotherapy.

On top of that there was the added complication of a bacterial infection contracted in hospital which threatened her life.

Despite all of this, during her first year in hospital Molly sat her Nationals exams in hospital and scored straight As.

In August last year she achieved straight As in her Highers and won a place at Oxford University's international summer school through all her hard work.

Weeks later Molly was told she would have to have another operation to remove one tumour, with chemo to target two more and stem cell bone marrow transplants.

During her cancer battle Molly has won the hearts of a number of celebrities, including Simon Cowell, Gary Barlow and Paulo Nutini, thanks to her fundraising exploits.

Together with her best friend Sara Millar she organised a fundraising ball last October to say thanks to all the hospital staff who have helped her.

Molly was also the first ever winner of the Rosie Mitchell Memorial Award at the Greenock Telegraph's Community Champions night last year.

Molly has now been shortlisted for Young Scotswoman of the Year hosted by Newsquest, which owns the Greenock Telegraph.

The public vote is open now and locals can back Molly up until until 5pm today.

The winner will be announced at the glittering gala in association with the St Enoch Centre, at the Grand Central Hotel on March 26.

Go here to see the original:
Brave Gourock teen battling bone cancer is in line for the Young Scot of the year award - Greenock Telegraph

Read More...

Michael Schumacher reportedly underwent breakthrough treatment; Here are details of the secret procedure – EconoTimes

February 25th, 2020 5:41 pm

Michael Schumacher turned 51 in January and as he became a year older, his fans are hoping that he is doing fine. Apparently, fans did not stop supporting him even if he not visible since his sustained massive brain injury due to a freak accident while he was skiing in December 2013.

A few weeks after the accident, Schumachers family refused to release information about the F1 champs health recovery. The family completely shut down the media so fans were deprived of information as to what is going on and any development in Schumis health. The secrecy went on for years and up to now, they remained secretive when it comes to the motorsport legends condition.

Secret treatment

It has been over six years since Micheal Schumacher had an accident and since then, some new treatments were developed. It was reported that the former sportsman tried out one of the latest procedures available today and it is called the stem cell treatment.

The Telegraph reported that Schumi was brought to Paris and admitted at the Georges-Pompidou hospital in September. The procedure was supposedly carried out by cardiovascular surgeon Philippe Menasch and it was said that one of the medical staff attested that Schumacher is conscious after the stem-cell procedure, a treatment dubbed as the pioneer in cell surgery."

It was said that Michael Schumacher stayed at the hospital for three days and on the last day, he was transported back to his home in Switzerland via ambulance. The question is - did he improved after the treatment?

How is he today?

As per The Daily Mail, even the surgeon who performed the procedure on Michael Schumacher said that he doesnt perform miracles. It appears he is saying that even though the treatment is considered a breakthrough in the medical field today, it may not work for everyone. With the racers condition, he may have developed some kind of complications that could have made his health situation worst and this treatment may have not affected Schumi as it should.

It is believed that Michael Schumacher is still paralyzed and being nursed on his bed. His movements are still limited and If there are improvements, perhaps, he could talk a bit and move some parts of his body like his head.

Read more here:
Michael Schumacher reportedly underwent breakthrough treatment; Here are details of the secret procedure - EconoTimes

Read More...

Who is most at risk of contracting coronavirus? – The Guardian

February 24th, 2020 11:46 am

There have been a number of deaths from the coronavirus among doctors who are young and, as far as we know, otherwise healthy.

According to Dr Bharat Pankhania, an expert on communicable disease control at the University of Exeter Medical School, it is not surprising that some young, healthy people die after contracting the virus, noting the risk of infection and even death is not zero for any demographic.

All of us are at risk, and hence the superlative efforts at keeping containment in place, and keeping the virus from circulating as much as we can do, he said.

David Heymann, professor of infectious disease epidemiology at the London School of Hygiene and Tropical Medicine, agreed. This is a new disease in humans, so no-one has immunity health workers, like everyone else, dont have immunity, he said.

What is Covid-19 - the illness that started in Wuhan?

It is caused by a member of the coronavirus family that has never been encountered before. Like other coronaviruses, it has come from animals. Many of those initially infected either worked or frequently shopped in the Huanan seafood wholesale market in the centre of the Chinese city.

Have there been other coronaviruses?

Severe acute respiratory syndrome (Sars) and Middle Eastern respiratory syndrome (Mers) are both caused by coronaviruses that came from animals. In 2002, Sars spread virtually unchecked to 37 countries, causing global panic, infecting more than 8,000 people and killing more than 750. Mers appears to be less easily passed from human to human, but has greater lethality, killing 35% of about 2,500 people who have been infected.

What are the symptoms caused by the new coronavirus?

The virus can cause pneumonia. Those who have fallen ill are reported to suffer coughs, fever and breathing difficulties. In severe cases there can be organ failure. As this is viral pneumonia, antibiotics are of no use. The antiviral drugs we have against flu will not work. Recovery depends on the strength of the immune system. Many of those who have died were already in poor health.

Should I go to the doctor if I have a cough?

UK Chief Medical Officers are advising anyone who has travelled to the UK from mainlandChina, Thailand, Japan, Republic of Korea, Hong Kong, Taiwan, Singapore, Malaysia or Macau in the last 14 days and who is experiencing a cough or fever or shortness of breath to stay indoors and call NHS 111, even if symptoms are mild.

Is the virus being transmitted from one person to another?

Chinas national health commission has confirmed human-to-human transmission, and there have been such transmissions elsewhere.

How many people have been affected?

As of 20 Februrary, China has recorded 2,118 deathsfrom the Covid-19 outbreak.Health officials have confirmed74,576 casesin mainlandChinain total. More than 12,000 have recovered.

The coronavirus has spread to at least 28 other countries. Japan has 607 cases, including 542 from a cruise ship docked in Yokohama, and has recorded one death. There have also been deaths in Hong Kong, Taiwan, France and the Philippines.

There have been nine recorded cases and no fatalities to date in the UK. As of 17 February, a total of 4,501 people have been tested in the UK, of which 4,492 were confirmed negative.

Why is this worse than normal influenza, and how worried are the experts?

We dont yet know how dangerous the new coronavirus is, and we wont know until more data comes in. The mortality rate is around 2% at the centre of the outbreak, Hubei province, and less than that elsewhere. For comparison, seasonal flu typically has a mortality rate below 1% and is thought to cause about 400,000 deaths each year globally. Sars had a death rate of more than 10%.

Another key unknown is how contagious the coronavirus is. A crucial difference is that unlike flu, there is no vaccine for the new coronavirus, which means it is more difficult for vulnerable members of the population elderly people or those with existing respiratory or immune problems to protect themselves. Hand-washing and avoiding other people if you feel unwell are important. One sensible step is to get the flu vaccine, which will reduce the burden on health services if the outbreak turns into a wider epidemic.

Is the outbreak a pandemic?

A pandemic, in WHO terms, is the worldwide spread of a disease. Coronavirus cases have been confirmed outside China, but by no means in all 195 countries on the WHOs list. It is also not spreading within those countries at the moment, except in a very few cases. By far the majority of cases are travellers who picked up the virus in China.

Should we panic?

No. The spread of the virus outside China is worrying but not an unexpected development. The WHO hasdeclared the outbreak to be a public health emergencyof international concern. The key issues are how transmissible this new coronavirus is between people, and what proportion become severely ill and end up in hospital. Often viruses that spread easily tend to have a milder impact. Generally, the coronavirus appears to be hitting older people hardest, with few cases in children.

Sarah Boseley,Hannah DevlinandMartin Belam

Heymann said that who succumbs to the infection and who shrugs it off is often down to individual differences in the bodys response to the virus.

Some groups have a greater risk than others. At the moment it appears that people who are at greater risk are the elderly and probably the very young, said Pankhania.

But, he added, you cannot have that only the elderly and the very young will die, it is part of the natural history of such infections that we will get deaths across the age ranges The same pathophysiology can happen in the young as in the old.

In short, yes. It is not surprising that fellow clinical colleagues have got infected and some have died, said Pankhania, noting that medical professionals were in a special situation as they had multiple potential exposures to infection.

You have got infection control in place, however if you are forever being targeted, on the one rare occasion where your guard slipped, you get infected, he said. It is like being in the battlefield no matter how much protection you have, a stray bullet can catch you sometimes.

Such a slip, he added, was not surprising. A minor slip is eminently possible, especially when you are working under stress, you are tired, you have done long hours and your guard falls and you get infected, he said.

Pankhania said that at present it was thought there was only one form of the virus in circulation, so doctors were not being exposed to a more serious strain.

But Heymann said that if doctors did become exposed to the virus, it might be in a higher dose than would have occurred in a social context for example, they might come into contact with bodily fluids. If there is a massive inoculum of virus, that could make it a more overwhelming infection, he said.

That is a tricky question. Heymann said there was evidence that some patients in China infected with coronavirus also had flu at the same time. If that were the case, this could possibly increase the severity of a coronavirus infection, just because the body is already fighting [flu], and it might overwhelm the system, he said, but added that remained a theory.

However Heymann noted prior exposure to all sorts of bugs meant that health workers in general tended to have quite robust immune systems.

In a clinical setting you need full personal protective equipment, so you would be fully gowned, said Pankhania, adding that airtight masks were also used. You can only breathe through the filter on that mask.

Goggles were used, he added, noting it was possible to be infected through the eyes, while gloves were also important.

A colleague has to watch you put [the equipment] on and a colleague has to watch you take it off, and you would systematically put it on and systematically take it off, said Pankhania. Otherwise you risk contaminating yourself in the process of taking it off. But he added that under stress, mistakes could happen.

Pankhania said the 1918 flu pandemic offered one possibility, noting that some young people showed an exuberant immune response in other words, their immune system reacted too strongly to infection. In some cases, as yet poorly explained, poorly understood, the immune response is over the top that immune response then turns itself upon the persons body itself, he said, adding that could lead to fluid loss and organ damage. Buthe said it was not yet clear if this was at play in the current coronavirus outbreak.

The question remains open, but this week the World Health Organization director-general, Tedros Adhanom Ghebreyesus, told reporters that a number of trials were under way looking at the potential use of two HIV drugs as well as another antiviral called remdesivir that was developed to tackle haemorrhagic fevers including Ebola. Results, it seems, may be expected in three to four months. Meanwhile Columbia University researchers have received a $2m (1.5m) grant to work on possible antivirals drugs and antibodies to tackle coronavirus.

There are a lot of unknowns, including whether the virus could mutate to a more virulent form, while Pankhania said experts were still looking at the rate of deaths among those infected.

One key number is known as the R0, or basic reproduction number, which indicates how many new cases an infected person generates. At present it is thought to be about 2.6.

However, Pankhania said there was reason to be cautiously optimistic, noting that the figure might be lower outside of China, not least since other countries have had prior warning of the virus, while Wuhan is a densely populated city. He urged people in the UK to stay calm and said there was no reason to give up social events, quit the gym or keep children from playdates.

That is absolutely overreacting, he said. At this point in time there is no coronavirus circulating in the UK in a free way.

No, it is important to try to contain the coronavirus. A new virus has emerged out of the blue, said Pankhania, adding that it was believed to have started in bats, entered another animal and then passed to humans. It can not only infect humans, but be transmitted among humans and cause disease, he said. The upshot is the potential for a new virus circulating around the globe causing illness and death.

It is an extra burden on humanity, an extra infection in addition to influenza, and there is also an unknownness about it, which is we dont know how many people it could make very ill, we dont know how many people it will take, hence our concerns, he said.

Excerpt from:
Who is most at risk of contracting coronavirus? - The Guardian

Read More...

Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101, an IL-2 Mutein Fc Fusion Therapy for Autoimmune Disease – Yahoo Finance

February 24th, 2020 11:46 am

Trial to evaluate safety and tolerability of PT101, as well as expansion of regulatory T cells

Pandion Therapeutics, Inc., a biotechnology company developing modular protein therapeutics for autoimmune disease, today announced the dosing of the first subject in a Phase 1 clinical trial of PT101, a novel and proprietary interleukin 2 (IL-2) mutein Fc fusion protein therapy. PT101 has shown potential to treat autoimmune diseases by expanding populations of regulatory T cells.

"PT101, the lead program in our pipeline of modular protein therapeutics, has the potential to transform the standard of care for patients with a wide array of autoimmune diseases by modulating the immune system through the bodys natural mechanisms, rather than suppressing it," said Rahul Kakkar, MD, chief executive officer of Pandion. "We are extremely pleased to announce the commencement of this first-in-human trial less than three years after we launched Pandion and began discovery work on PT101."

The Phase 1 clinical trial will assess the safety, tolerability, and pharmacokinetics of PT101 in healthy volunteers and will include measures of its pharmacodynamic and immuno-modulatory activity. The trial is designed to demonstrate the safety of PT101 and confirm its ability to expand regulatory T cell populations in human subjects. Pandion intends to investigate PT101 as a treatment for patients with ulcerative colitis and other autoimmune diseases.

In preclinical studies, PT101 demonstrated highly potent and selective expansion of regulatory T cells across a broad dose range. Toxicology studies with PT101 further support a wide therapeutic window and no evidence of toxicity associated with treatment.

"Significant need remains in the treatment of many autoimmune and inflammatory conditions," said Jo Viney, PhD, chief scientific officer of Pandion. "Treatment with low doses of interleukin 2 to expand regulatory T cells has shown promise in treating autoimmune diseases, but a narrow therapeutic index and frequent dosing make such therapy challenging. PT101s novel, proprietary design has achieved high selectivity for the expansion of regulatory T cells. We look forward to evaluating PT101s safety and selectivity in the clinic this year."

About PT101PT101 is an interleukin 2 (IL-2) mutein Fc fusion protein therapy designed to potently and selectively expand regulatory T cells for the treatment of autoimmune disease. Pandions Phase 1 trial of PT101 is designed to assess the safety, tolerability, and pharmacokinetics of PT101 after subcutaneous administration, and will also include measures of regulatory T cell expansion and other pharmacodynamic measures.

About PandionPandion Therapeutics is developing modular biologics for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases. The company is developing its lead drug candidate, PT101, an IL-2 mutein Fc fusion protein that preferentially expands regulatory T cells, as well as a robust pipeline of systemic immune modulators and tissue-targeted therapeutics focused on the gut, liver, skin, kidneys, and pancreas. Pandions approach to developing modular proteins, antibodies and bispecifics includes two key elements: first, the innovative biologics are based on cutting-edge immunomodulators such as an IL-2 mutein or PD-1 agonist that work systemically by activating regulatory pathways of the immune system that suppress uncontrolled autoimmune responses; and second, these immunomodulators can be combined with tissue-selective tethers, building modular proteins and antibodies that target the precise location within the organ to deliver the desired effect. Pandion is backed by leading life sciences investors including Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, BioInnovation Capital, and the JDRF T1D Fund. The company is headquartered in Cambridge, Massachusetts. Please visit http://www.pandiontx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200224005192/en/

Contacts

Media:Kathryn MorrisThe Yates Network914-204-6412kathryn@theyatesnetwork.com

Investors:Sarah McCabeStern Investor Relations, Inc.212-362-1200Sarah.mccabe@sternir.com

Read the original post:
Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101, an IL-2 Mutein Fc Fusion Therapy for Autoimmune Disease - Yahoo Finance

Read More...

Q&A: The curious case of male pregnancy in seahorses and pipefishes – Horizon magazine

February 24th, 2020 11:46 am

She is studying three of the different types of pregnancy in syngnathids, a fish family including seahorses, pipefish and seadragons as part of a project called MALEPREG. One type is when eggs are glued to the body of the male, who then carries them; the second is full male pregnancy, with transfer of nutrients and oxygen in a placenta-like system including one in which a pouch closes with a skin fold upon egg deposition; and the third is similar to the second but with a closed pouch.

Beyond the novelty value, what is so interesting about studying male pregnancy?

When its a normal pregnancy system, egg production and pregnancy all intermingle with the mother, so its very difficult to differentiate what happens during egg development and pregnancy.

(Another) reason is that when we want to understand the evolution of a trait, when we only have the absence or presence of this trait then its very difficult to study how it has evolved. In syngnathids, what we have is that male pregnancy has evolved on a gradient so we have closely related species that do display different forms.

If we compare those, then we can understand, OK, these genes have (provided) the function for this and this, and now this has happened.

What exactly are you looking at?

One of the main issues were studying is the problem of the immune system. If you accept a non-self embryo because half is from the father and half from the mother in your body, then your body would in principle (reject it). (So for pregnancy to evolve), somehow this rejection has to be circumvented.

In mammalians, (certain immune system) genes are downregulated (during pregnancy) this is why we see that pregnant individuals are often sick. Then there are specific adaptations in the placenta that prevent the rejection of this non-self tissue. We are studying this in syngnathids.

We are doing a comparative genomics approach, so we have sequenced genomes of these different (syngnathid) forms. What we have found is that those genes are lost (in syngnathids with a part-closed pouch and changed in those with a closed one). So one arm of the immune system thats really important for vertebrates is (functionally) entirely lost.

What are the implications of that finding?

Our hypothesis is that this has permitted the evolution of male pregnancy.

When we look at fishes, in general, the parental investment strategies are completely different from humans males have a more important role. For the syngnathids, the problem is that they dont have a stomach, so they have to feed more or less permanently. They are always hunting food. So probably thats why they started to carry (their eggs) with them.

When we look at those species that are only carrying these embryos with them on the belly, those still have a (fully) functional immune system. Only with the evolution of this placenta-like structure full male pregnancy is this part of the immune system lost. Potentially, this (loss) has permitted this extreme evolution.

(Also), we have (here) a system that basically is immunologically deficient. (This) can ultimately help human medicine, because there are so many immunodeficiency diseases (such as HIV) and we are not able to cope with them. (It suggests that theres) a lot more flexibility in the adaptive immune system or in the evolution of adaptive immunity than we thought earlier.

What else have you found so far?

We did transplant experiments to understand better this self/non-self recognition. We transplanted fins (tissue) of the syngnathids to the belly of (themselves and others) to see if they rejected it or not and what we have found there is that those that have lost parts of their immune system are a lot better-accepting of non-self tissues.

We compared (syngnathid pregnancy) genes to the mammalian pregnancy genes, and we actually do find that these are genes from the very same pathways: similar genes have been co-opted in their function towards pregnancy.

(This) suggests that there are not probably so many options in what things have to be changed in their functions (to allow pregnancy). It doesnt really give us an idea of why (pregnancy) has evolved, but more that convergent evolution can come with a similar mechanistic basic.

What are you looking at next?

Now we know which genes might be involved (in the evolution of male pregnancy), but we dont know their function yet. The next step will be to (definitively) identify these.

Then we can study how (these genes) have evolved across the phylogeny (family tree of organisms) and see, for example, where there are mutations involved. We know that in (male) pregnancy they seem to have a role, but not if this is the same function as they have in female pregnancy.

Were (also) working on all the microbiota involved (in syngnathids brood pouches). Weve cultivated these microbes and now were going to deplete all the microbes on the male side and then add them again to see what their function is, to really understand this co-evolution of pregnancy with the immune system, but also with these microbes.

(With parts of the immune system lost, were studying in addition) how is it possible that these fishes can survive and fight against diseases? And what kinds of compensatory mechanisms might they have?

What wider lessons can we draw from studying male pregnancy in syngnathids?

In reproduction, I think we still (often) have the understanding that males are the ones giving the sperm and they dont then have a big function in parental investment. But we know now in terms of epigenetics (gene expression) that fathers are providing a lot more than just the sperm.

In the syngnathids, we really have the chance to see, OK, the males have this and this function. There are so many classical perceptions about how males have to behave and how females have to behave, (but it may not always be the case). We should really go beyond model systems. When we are driven to go and look at these weird creatures, we can (better) understand nature.

The research in this article was funded by the European Research Council. If you liked this article, please consider sharing it on social media.

Read the rest here:
Q&A: The curious case of male pregnancy in seahorses and pipefishes - Horizon magazine

Read More...

Page 689«..1020..688689690691..700710..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick